Selective IKK/NF-kB Inhibitors for Genotoxic Stress
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer associated with genotoxic stress-induced iKK/NF-κB activation lack specific inhibitors that target only this pathway, leading to broad immunosuppression and severe side effects due to non-specific inhibition of NF-κB pathways.
Innovation Solution
Development of novel compounds that selectively inhibit the genotoxic stress-induced iKK/NF-κB pathway by interfering with specific protein-protein interactions and post-translational modifications, such as SUMOylation and phosphorylation, without affecting other NF-κB activation pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum NF-κB pathway inhibitors are used to treat cancer associated with genotoxic stress-induced IKK/NF-κB activation, then the therapeutic effect is achieved, but broad immunosuppression and severe side effects occur due to non-specific inhibition of other NF-κB pathways
Solution Approach 1:
The patent segments the NF-κB activation pathways by developing compounds that specifically inhibit only the genotoxic stress-induced IKK/NF-κB pathway while leaving other NF-κB pathways (such as those activated by inflammatory cytokines, TLR ligands, and bacterial toxins) unaffected. This selective inhibition eliminates broad immunosuppression and severe side effects while maintaining therapeutic efficacy against cancer.
Solution Approach 2:
The patent applies local quality by creating compounds with specific molecular structures (Formulae I-VII with defined substituents R1-R16) that confer selectivity for the genotoxic stress-induced pathway. The compounds possess specific structural features that enable them to distinguish and inhibit only the IKK complex activation triggered by DNA damage, while sparing other activation mechanisms.
2Object-affected harmful factors
If genotoxic stress-induced IKK/NF-κB pathway is selectively inhibited, then side effects are reduced and prolonged treatment is possible, but specific inhibitors that target only this pathway were previously unavailable
Solution Approach 1:
The patent employs parameter changes by systematically varying molecular parameters (substituents R1-R16 in Formulae I-VII) to optimize compound selectivity and potency. By adjusting these chemical parameters, the invention achieves compounds that specifically target the genotoxic stress-induced pathway with sub-micromolar concentrations, enabling prolonged treatment without immunosuppression.
3Reliability
If compounds are used at sub-micromolar concentrations to achieve selective inhibition, then therapeutic efficacy is maintained, but the concentration requirement is more stringent than conventional inhibitors
Solution Approach 1:
The patent replaces the mechanical/system-level approach of using high concentrations of non-specific inhibitors with a molecular-level solution. The compounds achieve high selectivity and potency through specific molecular interactions (inhibiting SUMOylation and phosphorylation events unique to the genotoxic pathway), allowing effective treatment at sub-micromolar concentrations with precise control.
Data Source
Figure 1
Figure 2
Figure 3A~3D
AI summary
The invention relates to chemical compounds and their use as a medicament in the treatment of a disease associated with genotoxic stress-induced I KK/NF-κΒ (NF-kappaB) activation, preferably in the treatment of a subject suffering from cancer exhibiting genotoxic stress-induced I KK/NF-κΒ activation. The invention further relates to a pharmaceutical composition comprising a compound of the invention for the treatment of a subject afflicted by a disease associated with genotoxic stress-induced I KK/NF-κΒ activation.